43.13
-2.27 (-4.99%)
| Previous Close | 45.40 |
| Open | 45.01 |
| Volume | 2,389,833 |
| Avg. Volume (3M) | 1,477,550 |
| Market Cap | 3,874,721,792 |
| Price / Earnings (Forward) | 23.36 |
| Price / Sales | 18.15 |
| Price / Book | 1.93 |
| 52 Weeks Range | |
| Earnings Date | 17 Feb 2025 - 3 Mar 2025 |
| Profit Margin | -118.13% |
| Operating Margin (TTM) | -18,294.02% |
| Diluted EPS (TTM) | -2.79 |
| Quarterly Revenue Growth (YOY) | -99.30% |
| Total Debt/Equity (MRQ) | 11.73% |
| Current Ratio (MRQ) | 21.64 |
| Operating Cash Flow (TTM) | -188.82 M |
| Levered Free Cash Flow (TTM) | -118.57 M |
| Return on Assets (TTM) | -9.57% |
| Return on Equity (TTM) | -13.07% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | CRISPR Therapeutics AG | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.5 |
| Average | -0.38 |
|
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Core |
| % Held by Insiders | 1.69% |
| % Held by Institutions | 83.82% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 94.00 (Chardan Capital, 117.92%) | Buy |
| Median | 84.00 (94.74%) | |
| Low | 53.00 (RBC Capital, 22.87%) | Hold |
| Average | 74.40 (72.48%) | |
| Total | 3 Buy, 2 Hold | |
| Avg. Price @ Call | 48.16 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JMP Securities | 20 Dec 2024 | 86.00 (99.37%) | Buy | 39.95 |
| Chardan Capital | 10 Dec 2024 | 94.00 (117.92%) | Buy | 48.68 |
| Barclays | 06 Nov 2024 | 55.00 (27.51%) | Hold | 50.72 |
| Needham | 06 Nov 2024 | 84.00 (94.74%) | Buy | 50.72 |
| RBC Capital | 06 Nov 2024 | 53.00 (22.87%) | Hold | 50.72 |
| 04 Oct 2024 | 53.00 (22.87%) | Hold | 45.37 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 09 Dec 2024 | Announcement | CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting |
| 14 Nov 2024 | Announcement | CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference |
| 07 Nov 2024 | Announcement | CRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference |
| 05 Nov 2024 | Announcement | CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |